Latest Anastrozole Stories
There is good news for postmenopausal women who are at high risk for developing breast cancer. According to a new study, taking the drug anastrozole for five years reduced the likelihood of developing the disease by 53 percent when compared with women who took a placebo.
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole.
New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress gynecomastia and breast pain in men.
Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives.
A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy.
Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer.
- A serpent whose bite was fabled to produce intense thirst.